Not much. The 4C for OCC is pretty standard $200k receipts, $1.5m expenses. $17.7m cash at the end of Q3.
This when it comes to pass is the result we're looking for:
This reimbursement will assist the Company in pursuing negotiations with multi-national dental companies and national dealers for marketing and distribution rights, with Orthocell to retain manufacturing of the finished product. With US, EU and Australian market approval achieved and key opinion leaders (KOLs) actively engaging with the program, Orthocell is well positioned to secure distribution partners and establish Striate+TM as the premium dental collagen membrane.
Not much. The 4C for OCC is pretty standard $200k receipts,...
-
- There are more pages in this discussion • 1,170 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
0.005(1.32%) |
Mkt cap ! $80.59M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 39.0¢ | 38.5¢ | $17.64K | 45.67K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 23269 | 38.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 25000 | 2 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |